semaglutide fda approval date weight loss A stronger 7.2 mg dose of Wegovy wins after a 54-day review, promising greater for eligible patients. || FULL STORY IN COMMENTS Modern data confirm GLP-1 -Primary Health Interest: Sexual Health Size:60 Count

semaglutide fda approval date weight loss A stronger 7.2 mg dose of Wegovy wins after a 54-day review, promising greater for eligible patients. || FULL STORY IN COMMENTS Modern data confirm GLP-1 -Primary Health Interest: Sexual Health Size:60 Count

Modern data confirm GLP-1 agonists are not linked to pancreatitis. | Gerti Tashko, MD

Weight loss during weeks eight through twelve often ranges from six to twelve pounds, continuing the momentum established in earlier weeks

-Primary Health Interest: Sexual Health

Size:60 Count

3 In January 2026, the FDA published the largest review to date, analysing 91 placebo-controlled GLP-1 trials covering 107,910 patients alongside a real-world cohort study of 2.2 million patients